Biography
Dr. Sakul led implementation of Pfizer’s diagnostics strategy and currently directs its Diagnostics programs. He led Pfizer’s flagship CDx program (Xalkori®) to US approval in 2011. Under his leadership, FDA approvals were achieved for 7 CDx tests accompanying Pfizer oncology drugs to markets, with 26 global approvals to date. He worked in biotech in human genetics and statistical genetics fields early in his career before moving to pharma. He serves on the Boards of The Personalized Medicine Coalition, and Progentec Diagnostics, is a member of the Oncology Advisory Board of Luminex Corp, and a member of California Governor Newsom’s Precision Medicine Advisory Council. He is the author of over 30 refereed scientific articles as well as many other papers and abstracts. Hakan is keenly interested in molecular diagnostics, liquid biopsy, near-patient testing and related medical technologies to advance Precision Medicine for the improvement of individualized healthcare.